A recent scientific investigation originating from Brazil has brought to light compelling new data suggesting that prolonged reliance on a class of medications widely prescribed for digestive ailments, known as proton pump inhibitors (PPIs), might significantly impede the body’s capacity to assimilate essential micronutrients, with potential ramifications for bone health and the development of anemia. This research initiative was spearheaded by a collaborative team of scientists affiliated with the Federal University of São Paulo (UNIFESP) and the ABC Medical School (FMABC). Within the pharmaceutical landscape, PPIs encompass frequently utilized agents such as omeprazole (marketed as Prilosec), pantoprazole (Protonix), and esomeprazole (Nexium), which are standard treatments for conditions ranging from peptic ulcers and gastritis to the discomforts of acid reflux.
While these pharmaceutical compounds have demonstrated considerable efficacy in curtailing the production of stomach acid, thereby alleviating symptoms associated with hyperacidity, their application beyond the duration stipulated by medical professionals could precipitate a cascade of adverse effects. These include the emergence of nutrient deficiencies, notably anemia, and a detrimental impact on the structural integrity of bones. The findings derived from this critical study have been formally documented and disseminated through publication in the esteemed scientific journal, ACS Omega.
The research team, bolstered by financial support from the São Paulo Research Foundation (FAPESP), embarked on an in-depth examination of the effects of sustained omeprazole administration on the absorption and distribution of several crucial minerals in a preclinical model. Their focus encompassed key elements vital for physiological function, including iron, calcium, zinc, magnesium, copper, and potassium. Observations revealed distinct alterations in the systemic distribution of these minerals among the animal subjects subjected to the medication.
Evidence indicated that omeprazole appeared to facilitate the accumulation of certain minerals within the stomach lining, concurrently fostering imbalances in their concentrations within the liver and spleen. Subsequent hematological analyses unveiled elevated levels of calcium in the bloodstream, juxtaposed with diminished iron concentrations. These biochemical shifts are intrinsically associated with an increased susceptibility to conditions such as osteoporosis, a disease characterized by weakened bones, and anemia, a state of insufficient red blood cells or hemoglobin. Furthermore, the researchers meticulously documented noteworthy modifications within immune system cells, hinting at broader physiological disturbances.
To rigorously assess these potential impacts, the experimental protocol involved the division of adult rats into two distinct cohorts: a control group, which received no intervention, and an experimental group that was administered omeprazole. The duration of omeprazole treatment was strategically varied, spanning periods of 10, 30, and 60 days, to effectively simulate diverse scenarios of prolonged medication use as might occur in human patients.
Angerson Nogueira do Nascimento, a distinguished professor at UNIFESP who co-led this comprehensive study alongside Fernando Fonseca from FMABC, articulated a particularly concerning observation: "The most worrying finding was the significant increase in calcium in the animals’ bloodstream, which may indicate an imbalance with the removal of the mineral from the bones and a future risk of osteoporosis. However, longer studies are needed to confirm this hypothesis." This statement underscores the potential for a disruption in calcium homeostasis, a critical process for maintaining bone density and preventing fractures.
The fundamental mechanism by which proton pump inhibitors exert their therapeutic action involves the targeted inhibition of the H+, K+-ATPase enzyme, commonly referred to as the proton pump. This enzyme plays a pivotal role in the terminal stage of hydrochloric acid synthesis within the gastric environment. By effectively suppressing the secretion of gastric acid, these medications provide symptomatic relief for a spectrum of gastrointestinal disorders, including ulcers, gastritis, and reflux disease.
However, a crucial aspect of gastric acid’s physiological role extends beyond digestion; it is also instrumental in facilitating the absorption of specific nutrients. When the natural production of stomach acid is curtailed over extended durations, the body’s ability to assimilate minerals that are dependent on an acidic milieu for optimal uptake may become compromised. This impaired absorption can subsequently lead to systemic deficiencies, contributing to the adverse health outcomes observed in the study.
The widespread availability and frequent utilization of omeprazole, a drug that has been on the market for over three decades, coupled with its over-the-counter accessibility in some regions, have amplified concerns regarding potential overuse and self-medication. Andréa Santana de Brito, a researcher at UNIFESP whose master’s research provided the foundational framework for this study, emphasized this point: "It isn’t a question of demonizing the drug, which is effective for various gastric conditions. The problem is its trivialized use, even for mild symptoms such as heartburn, and for prolonged periods of months and even years. Its adverse effects shouldn’t be overlooked." This sentiment highlights a disconnect between the drug’s therapeutic utility and its potentially indiscriminate application.
Further exacerbating these concerns is a recent regulatory development in Brazil, where the National Health Surveillance Agency (ANVISA) authorized the over-the-counter sale of 20mg omeprazole formulations in November 2025. Ms. de Brito warned that this increased accessibility might inadvertently encourage individuals to self-medicate and continue using the drug indefinitely, disregarding the recommended treatment limitation of 14 days. Such practices could circumvent necessary medical evaluations and lead to the undetected progression of nutrient deficiencies or other adverse effects.
In response to these evolving regulations, ANVISA has articulated its position, asserting that making 20mg omeprazole available without a prescription is intended to foster responsible medication use. The agency characterizes this regulatory shift as "a step forward in rationalizing its use and promoting its safe and responsible use." ANVISA further clarified that by strictly limiting treatment to a maximum of 14 days, the underlying message is reinforced that the drug should be reserved for the relief of mild and transient symptoms, thereby prompting individuals to seek professional medical attention should their symptoms persist or recur. The agency also stated that comprehensive instructions regarding the duration of use, warning signs, and potential drug interactions will be clearly delineated on product packaging and inserts, empowering consumers to make informed decisions. Crucially, ANVISA has stipulated that packaging containing more than a 14-day supply of omeprazole will remain prescription-only.
While the experimental focus of this particular investigation was on omeprazole, the researchers strongly emphasize that the physiological mechanisms at play are shared by other medications within the PPI class. Newer agents such as pantoprazole and esomeprazole, which operate on similar principles, may even exert a more pronounced impact due to their enhanced potency and extended duration of action. Ms. de Brito elaborated on this point: "In these cases, the effect may be even more intense since these molecules have a more potent and longer-lasting action. Some take more than five days to allow the formation of new proton pumps, while omeprazole takes about one to three days, which can intensify side effects." This comparison highlights the potential for greater physiological disruption with certain PPIs.
The scientific community has long recognized a correlation between the use of PPIs and a diminished capacity for nutrient absorption. However, this current research significantly broadens that understanding by incorporating an examination of a wider array of essential minerals, including magnesium and zinc, which were not as extensively studied in previous investigations. Professor Nogueira concluded by reiterating the paramount importance of judicious medication use: "We reinforce the importance of the rational use of these drugs and even of assessing the need for supplementation in some cases. However, medical supervision is necessary to evaluate each case individually." This underscores the need for a personalized approach to medication management, potentially involving dietary or pharmacological supplementation under the guidance of a healthcare professional to mitigate the risks associated with long-term PPI therapy.
About the Author
